Northpond Ventures, LLC

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Northpond Ventures, LLC reported 4 stock positions worth $55.3 million. Its top holding was Kyverna Therapeutics (KYTX) at 44.2% of the portfolio, followed by Vigil Neuroscience (VIGL, 30.5%) and Candel Therapeutics (CADL, 21.7%). Compared with Q1 2024, it reduced 1. The biggest sale was Telesis Bio (TBIO, shares −2%).

Most Recent 13F
Q3 2024
Location
Bethesda, MD
CIK
0001911245
Portfolio Value
$55.3M (Q2 2024)
SEC Filing
0001104659-24-089657 ↗ filed Aug 14, 2024

Holdings Value

0$50.0M$100.0M$150.0M Q1 2024: $102.6M Q1 2024 Q2 2024: $55.3M $55.3M Q2 2024 Q3 2024: $43.7M Q3 2024

Holdings 4 stocks · $55.3M
KYTX Kyverna Therapeutics Inc. 44.18% 3,255,426 $24.4M No change
VIGL Vigil Neuroscience Inc. 30.50% 4,214,498 $16.9M No change
CADL Candel Therapeutics Inc. 21.71% 1,935,215 $12.0M No change
TBIO Telesis Bio Inc. 3.61% 546,897 $2.0M Reduce -2.4%

Portfolio Sells Q1 2024 → Q2 2024
TBIO Telesis Bio Inc. Reduce -2.4% 3.61% −0.61

Portfolio Buys Q1 2024 → Q2 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 3$43.7MKYTX, VIGL, CADL
Q2 2024 4$55.3MKYTX, VIGL, CADL, TBIO
Q1 2024 4$102.6MKYTX, VIGL, TELESIS BIO INC, CADL